Risks

Working-capital intensity remains elevated, with a 229-day cash conversion cycle and 91-day receivables, which can pressure liquidity versus faster-turning peers.

Inventory and receivable days are both long, so slower cash realization can constrain reinvestment and amplify execution risk relative to more efficient healthcare peers.

Interest coverage is reported as deeply negative, indicating limited current earnings support for debt service and leaving BGM more exposed than peers with clearer operating coverage.

Current ratio of 1.25 and quick ratio of 0.65 suggest only modest near-term liquidity headroom, which can matter more than for peers with stronger cash buffers.

Net debt to EBITDA has risen to 1.12, but the benefit is offset by weak cash generation visibility, limiting BGM’s ability to absorb demand or reimbursement volatility versus peers.

Opportunities

If receivables collection improves, the large working-capital base can release cash quickly, creating a clearer liquidity uplift than peers with already efficient cycles.

Low net debt to EBITDA provides some balance-sheet flexibility, so any operating improvement could translate into faster deleveraging than for more levered peers.

The current ratio above 1.0 gives BGM a basic liquidity cushion, which can support continuity through near-term volatility better than sub-1.0 peers.

Because leverage is modest, incremental margin or volume gains should flow more directly to cash than at peers carrying heavier debt burdens.

Any normalization in inventory and payables timing could materially improve cash conversion, offering upside if BGM closes the efficiency gap with better-run peers.

Overall Score

BGM’s forward positioning is constrained by weak cash conversion, limited interest coverage, and only modest liquidity, while low leverage and working-capital normalization provide some upside versus peers.